Hematological Malignancy
Showing NaN - NaN of 5
Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Leukemia Trial in Worldwide (MT-3724
Terminated
- Non-Hodgkin's B-cell Lymphoma
- +5 more
- MT-3724 Phase 1
- MT-3724 Phase 2
-
Tucson, Arizona
- +40 more
Jul 18, 2022
Solid Tumor, Sars-CoV2, Hematological Malignancy Trial in New York (BMS-986253)
Terminated
- Solid Tumor
- +2 more
-
New York, New YorkColumbia University Irving Medical Center
Nov 18, 2021
Hematological Malignancy, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission Trial in New York (Cord blood
Completed
- Hematological Malignancy
- +5 more
- Cord blood stem cells
- +5 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai
May 20, 2021
Cancer, Hematological Malignancy Trial in New York (Pembrolizumab, Ruxolitinib)
Withdrawn
- Cancer
- Hematological Malignancy
-
New York, New YorkNew York University School of Medicine
May 26, 2020
Testing in Patients Undergoing Hematopoietic Cell
Completed
- Acute Myeloid Leukemia
- +5 more
- Symptom-limited cardiopulmonary exercise test (CPET)
- +4 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Apr 15, 2020